Teknova Inc (TKNO) - Long-Term Liabilities to Capital

Corporate emblem and logo of Teknova Inc (TKNO)

Alpha Teknova, Inc. (TKNO) minimizes risks by producing culture media and reagents for gene therapy and vaccines, ensuring sustainable sales. The business leverages significant pricing power through the rapid manufacturing of customized GMP solutions. The current metric stands at 0.40. This price chart is supplemented by data on the implementation of AI systems in the automation of biopharmaceutical filling and dosing.

Alpha Teknova Inc - TKNO Long-Term Debt to Capital (period 07/04/2022 - 10/30/2026)

Comprehensive metric breakdowns and analytics for Alpha Teknova, Inc. (TKNO)

- stock value and consensus price forecast:
Stock Quotes Alpha Teknova|TKNO - Analyst Consensus Forecast
- market capitalization indicators:
Market Value Alpha Teknova|TKNO - Enterprise Value
- book value of equity indicators:
Equity per Share Teknova|TKNO - Book Capitalization|Market Capitalization to Book Value teknova.com|TKNO - Company Total Assets
- debt and solvency information:
Total Debt to Equity Ratio Alpha Teknova, Inc.|TKNO - Long-Term Debt to Capital|Short-Term Debt to Capital teknova.com|TKNO - Company Debts|Debt to Book Capitalization Ratio Alpha Teknova|TKNO - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Teknova|Interim Coverage Ratio teknova.com
- financial results and valuation multiples details:
TKNO - Company Net Income
Comprehensive company analysis:Alpha Teknova
Signature product of Alpha Teknova, Inc.

To objectively assess the operational resilience of Alpha Teknova, Inc. (TKNO), investors must understand the company's degree of reliance on borrowed funds for asset financing. By analyzing the long-term debt-to-equity ratio, we compare liabilities with maturities exceeding one year against shareholders' equity, which allows for an evaluation of the issuer's financial cushion amid geopolitical instability and rising costs for chemical reagent supplies.

Competing companies

Long-Term Debt to Equity Ratio Intuitive Surgical, Inc. (ISRG)|Long-Term Debt to Capital DHR|BDX - Long-Term Liabilities to Capital|Long-Term Debt to Capital STE (STERIS plc)|WST: Long-Term Debt to Capital Ratio|Baxter - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Masimo Corp MASI|STVN: Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Teleflex Corp|MMSI (Merit Medical Systems) - Long-Term Debt to Capital|Long-Term Debt to Capital envistaco.com|Long-Term Debt to Equity ICU Medical (ICUI)|Long-Term Debt to Equity XRAY (Dentsply Sirona Inc)|LeMaitre - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient ATRC|STAAR Surgical Company - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital ChromaDex Corp NAGE|ZimVie (ZIMV) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio ANGO|Long-Term Debt to Equity Cerus Corp|Monogram Orthopedics Inc. (MGRM) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Ratio STSS (Sharps Technology, Inc.)|Long-Term Loans to Capital Ratio INFU|Long-Term Debt to Equity Utah Medical Products, Inc. UTMD|Long-Term Debt to Capital Coefficient KRMD|NYXH: Long-Term Debt to Equity Ratio|MBOT - Long-Term Debt to Capital|Pro-Dex, Inc. (PDEX) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio zentek.com|ELUT (Elutia) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Milestone Scientific Inc MLSS|Long-Term Debt to Equity NEXGEL, Inc (NXGL)|retractable.com - Long-Term Debt to Capital Ratio|Harvard Bioscience, Inc. - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio FEMY (femasys.com)|MHUA - Long-Term Debt to Equity|Ratio of Long-Term Indebtedness to Capital Predictive Oncology POAI|CJMB: Long-Term Debt to Capital|Atrion Corporation Inc. (ATRI) - Long-Term Debt to Capital|Long-Term Debt to Equity NeuroMetrix, Inc.